Icecure Medical Ltd(ICCM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.57 | Insider Own | 55.6% | Shs Outstand | 3.4M | Perf Week | -27.89% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 31.59% | Insider Trans | - | Shs Float | 1.5M | Perf Month | -40.01% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -1.16 | Inst Own | 14.33% | Short Float | 2.78% | Perf Quarter | -77.6% |
| Income | -0.02B | P/S | 0.6 | EPS this Y | 25.69% | Inst Trans | 0.63% | Short Ratio | 0.29 | Perf Half Y | -90.8% |
| Sales | 0.00B | P/B | 0.2 | EPS next 5Y | 32.04% | ROA | -119.31% | Short Interest | 0.04M | Perf YTD | -96.23% |
| Book/sh | 3.47 | P/C | 0.2 | EPS past 3/5Y | 19.27% 32.65% | ROE | -228.31% | 52W High | -96.93% ($22.50) | Perf Year | -96.76% |
| Cash/sh | 3.51 | P/FCF | - | Sales past 3/5Y | 3.08% -2.67% | ROIC | -141.65% | 52W Low | -8.01% ($0.75) | Perf 3Y | -96.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 20.47% | Gross Margin | 36.1% | Volatility(W/M) | 9.77% 10.4% | Perf 5Y | -99.69% |
| Dividend TTM | - | EV/Sales | -2.42 | Sales Y/Y TTM | 41.62% | Oper. Margin | -423.69% | ATR (14) | 0.12 | Perf 10Y | -98.53% |
| Dividend Ex-Date | - | Quick Ratio | 2.44 | EPS Q/Q | 22.14% | Profit Margin | -427.67% | RSI (14) | 15.51 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.87 | Sales Q/Q | 72.76% | SMA20 | -29.6% ($0.98) | Beta | 0.51 | Target Price | $19 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/12 | SMA50 | -55.01% ($1.53) | Rel Volume | 0.74 | Prev Close | $0.79 |
| Employees | 69 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -1.87% -37.46% | SMA200 | -90.85% ($7.54) | Avg Volume(3M) | 0.14M | Price | $0.69 |
| IPO | 2013/11/7 | Option/Short | No/Yes | Trades | 208 | Volume | 107,095 | Change | -12.74% |
A medical device company specializing in cryoablation, a treatment that destroys tumors by freezing them. Its core product, ProSense, is an FDA-approved device that treats breast and kidney cancer tumors without surgery. It uses liquid nitrogen to generate ultra-low temperatures below -170°C to eliminate tumors, and the company is headquartered in Israel.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
ICCM has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.7% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $60. Peers typically go for $143.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.3%.
Tap to view numbers
It ranks #135 of 140 in the industry
Based on market cap of $2M.
AIDX#132 20/20 Biolabs Inc $3M PER - 
BJDX#133 Bluejay Diagnostics Inc $2M PER - 
IVF#134 INVO Fertility Inc $2M PER - ICCM#135 Icecure Medical Ltd $2M PER - 
CODX#135 Co-Diagnostics Inc $2M PER - 
FAQ
What kind of company is ICCM?
ICCM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ICCM?
The market cap of ICCM is approximately $2M, ranking 5,758 within its sector.
What is the 52-week high and low for ICCM?
ICCM has recorded a 52-week high of $22.50 and a low of $0.75.
